- Home
- PERI vs ATAI Comparison
PERI vs ATAI Comparison
Compare PERI & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- ATAI
- Stock Information
- Founded
- PERI 1999
- ATAI 2018
- Country
- PERI Israel
- ATAI Germany
- Employees
- PERI N/A
- ATAI N/A
- Industry
- PERI EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- ATAI Health Care
- Exchange
- PERI Nasdaq
- ATAI Nasdaq
- Market Cap
- PERI 484.6M
- ATAI 444.7M
- IPO Year
- PERI 2006
- ATAI 2021
- Fundamental
- Price
- PERI $10.22
- ATAI $2.22
- Analyst Decision
- PERI Buy
- ATAI Strong Buy
- Analyst Count
- PERI 4
- ATAI 3
- Target Price
- PERI $11.50
- ATAI $10.50
- AVG Volume (30 Days)
- PERI 225.3K
- ATAI 2.7M
- Earning Date
- PERI 07-30-2025
- ATAI 08-12-2025
- Dividend Yield
- PERI N/A
- ATAI N/A
- EPS Growth
- PERI N/A
- ATAI N/A
- EPS
- PERI N/A
- ATAI N/A
- Revenue
- PERI $429,808,000.00
- ATAI $1,863,000.00
- Revenue This Year
- PERI N/A
- ATAI $554.22
- Revenue Next Year
- PERI $11.24
- ATAI N/A
- P/E Ratio
- PERI N/A
- ATAI N/A
- Revenue Growth
- PERI N/A
- ATAI 572.56
- 52 Week Low
- PERI $7.00
- ATAI $1.03
- 52 Week High
- PERI $11.79
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- PERI 56.20
- ATAI 53.76
- Support Level
- PERI $9.28
- ATAI $2.06
- Resistance Level
- PERI $10.04
- ATAI $2.51
- Average True Range (ATR)
- PERI 0.30
- ATAI 0.17
- MACD
- PERI 0.01
- ATAI -0.03
- Stochastic Oscillator
- PERI 79.20
- ATAI 46.08
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.